Warning: Javascript must be enabled within your browser's settings for this site to function properly.

Your browser appears to be out of date, and is not supported by this site. For the best experience, we recommend that you upgrade to a more modern browser. You can find a list of modern browsers from www.browsehappy.com.

We use technical and analytics cookies data to ensure that we give you the best experience on our website. For more information visit our Privacy Page.

BWXT $   $  
As of . Minimum 20 minute delay.

News

BWXT to Produce Medical Radioisotope Germanium-68 to Address Rise in Demand

30 October 2019

  Investors  Nuclear Medicine  Press Release

BWXT Announces Availability of FDA-Approved Indium In-111 Oxyquinoline Solution

25 September 2019

(LYNCHBURG, Va. – September 26, 2019) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT ITG Canada, Inc., having received approval from the U.S. Food and Drug Administration (FDA) on its abbreviated new drug application for its generic version of Indium In-111 Oxyquinoline Solution, is now making the product available for sale in the United States.

  Investors  Nuclear Medicine  Press Release